Relay Historical Balance Sheet

RLAY Stock

USD 2.86 0.10 3.38%

Trend analysis of Relay Therapeutics balance sheet accounts such as Total Stockholder Equity of 605 M, Other Liab of 21.6 M, Net Tangible Assets of 1.1 B or Property Plant And Equipment Net of 46.1 M provides information on Relay Therapeutics' total assets, liabilities, and equity, which is the actual value of Relay Therapeutics to its prevalent stockholders. By breaking down trends over time using Relay Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Relay Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Relay Therapeutics is a good buy for the upcoming year.

Relay Therapeutics Inventory

14.62 Million

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Relay Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Relay Stock please use our How to Invest in Relay Therapeutics guide.

About Relay Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Relay Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Relay Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Relay Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Relay currently owns. An asset can also be divided into two categories, current and non-current.

Relay Therapeutics Balance Sheet Chart

At this time, Relay Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Capital Surpluse is likely to rise to about 2.4 B in 2025, whereas Total Assets are likely to drop slightly above 855.6 M in 2025.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Relay Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Relay Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Relay Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Relay Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Relay Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Relay Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Relay Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Relay Stock please use our How to Invest in Relay Therapeutics guide.At this time, Relay Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Capital Surpluse is likely to rise to about 2.4 B in 2025, whereas Total Assets are likely to drop slightly above 855.6 M in 2025.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	57.7M	53.5M	48.5M	36.5M
Total Assets	1.1B	844.0M	871.3M	855.6M

Short Long Term Debt Total Total Assets

Relay Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital
Total Assets		0.86	0.8	0.87	0.99	0.85	0.95	0.85	0.68	-0.3	-0.82	0.82	0.37	0.86	0.77	0.75	1.0	0.95	0.92	-0.95	0.94	0.86	0.72	0.94	-0.94	0.99
Short Long Term Debt Total	0.86		0.74	0.91	0.86	0.69	0.88	1.0	0.88	0.1	-0.88	0.91	-0.02	1.0	0.76	0.76	0.83	0.91	0.92	-0.86	0.91	1.0	0.68	0.88	-0.84	0.86
Other Current Liab	0.8	0.74		0.93	0.72	0.61	0.69	0.75	0.64	-0.39	-0.64	0.76	0.45	0.75	0.65	0.68	0.8	0.71	0.73	-0.64	0.71	0.74	0.69	0.71	-0.61	0.72
Total Current Liabilities	0.87	0.91	0.93		0.83	0.71	0.83	0.91	0.8	-0.13	-0.84	0.92	0.21	0.92	0.79	0.83	0.86	0.86	0.9	-0.78	0.87	0.91	0.75	0.87	-0.75	0.83
Total Stockholder Equity	0.99	0.86	0.72	0.83		0.82	0.97	0.84	0.68	-0.22	-0.82	0.82	0.29	0.85	0.71	0.71	0.97	0.98	0.92	-0.98	0.94	0.86	0.7	0.95	-0.98	1.0
Other Liab	0.85	0.69	0.61	0.71	0.82		0.79	0.67	0.42	-0.31	-0.73	0.75	0.37	0.69	0.89	0.89	0.88	0.83	0.86	-0.75	0.8	0.69	0.6	0.82	-0.75	0.82
Net Tangible Assets	0.95	0.88	0.69	0.83	0.97	0.79		0.86	0.68	-0.03	-0.92	0.87	0.1	0.87	0.73	0.72	0.93	0.96	0.94	-0.99	0.99	0.88	0.82	0.96	-0.97	0.97
Property Plant And Equipment Net	0.85	1.0	0.75	0.91	0.84	0.67	0.86		0.91	0.09	-0.87	0.89	-0.01	1.0	0.77	0.77	0.82	0.89	0.91	-0.83	0.89	1.0	0.65	0.87	-0.81	0.84
Current Deferred Revenue	0.68	0.88	0.64	0.8	0.68	0.42	0.68	0.91		0.08	-0.71	0.69	-0.01	0.9	0.64	0.61	0.64	0.73	0.75	-0.67	0.72	0.88	0.38	0.74	-0.66	0.68
Net Debt	-0.3	0.1	-0.39	-0.13	-0.22	-0.31	-0.03	0.09	0.08		-0.24	0.14	-1.0	0.07	-0.17	-0.12	-0.36	-0.1	-0.01	0.05	0.03	0.1	0.13	-0.08	0.09	-0.22
Retained Earnings	-0.82	-0.88	-0.64	-0.84	-0.82	-0.73	-0.92	-0.87	-0.71	-0.24		-0.93	0.16	-0.88	-0.78	-0.8	-0.8	-0.87	-0.94	0.86	-0.96	-0.88	-0.85	-0.91	0.82	-0.82
Accounts Payable	0.82	0.91	0.76	0.92	0.82	0.75	0.87	0.89	0.69	0.14	-0.93		-0.07	0.9	0.76	0.84	0.8	0.89	0.94	-0.82	0.9	0.91	0.84	0.89	-0.79	0.82
Cash	0.37	-0.02	0.45	0.21	0.29	0.37	0.1	-0.01	-0.01	-1.0	0.16	-0.07		0.01	0.24	0.19	0.43	0.17	0.09	-0.12	0.05	-0.02	-0.08	0.15	-0.16	0.29
Non Current Assets Total	0.86	1.0	0.75	0.92	0.85	0.69	0.87	1.0	0.9	0.07	-0.88	0.9	0.01		0.79	0.78	0.83	0.9	0.92	-0.84	0.9	1.0	0.66	0.88	-0.82	0.85
Non Currrent Assets Other	0.77	0.76	0.65	0.79	0.71	0.89	0.73	0.77	0.64	-0.17	-0.78	0.76	0.24	0.79		0.96	0.8	0.76	0.86	-0.65	0.78	0.76	0.53	0.79	-0.62	0.71
Other Assets	0.75	0.76	0.68	0.83	0.71	0.89	0.72	0.77	0.61	-0.12	-0.8	0.84	0.19	0.78	0.96		0.78	0.79	0.89	-0.64	0.77	0.76	0.58	0.83	-0.63	0.71
Cash And Short Term Investments	1.0	0.83	0.8	0.86	0.97	0.88	0.93	0.82	0.64	-0.36	-0.8	0.8	0.43	0.83	0.8	0.78		0.93	0.91	-0.92	0.92	0.83	0.71	0.92	-0.91	0.97
Common Stock Total Equity	0.95	0.91	0.71	0.86	0.98	0.83	0.96	0.89	0.73	-0.1	-0.87	0.89	0.17	0.9	0.76	0.79	0.93		0.97	-0.96	0.94	0.91	0.7	0.98	-0.97	0.98
Common Stock Shares Outstanding	0.92	0.92	0.73	0.9	0.92	0.86	0.94	0.91	0.75	-0.01	-0.94	0.94	0.09	0.92	0.86	0.89	0.91	0.97		-0.91	0.96	0.92	0.75	0.98	-0.9	0.92
Non Current Liabilities Total	-0.95	-0.86	-0.64	-0.78	-0.98	-0.75	-0.99	-0.83	-0.67	0.05	0.86	-0.82	-0.12	-0.84	-0.65	-0.64	-0.92	-0.96	-0.91		-0.96	-0.86	-0.76	-0.94	0.99	-0.98
Capital Surpluse	0.94	0.91	0.71	0.87	0.94	0.8	0.99	0.89	0.72	0.03	-0.96	0.9	0.05	0.9	0.78	0.77	0.92	0.94	0.96	-0.96		0.91	0.84	0.96	-0.93	0.94
Capital Lease Obligations	0.86	1.0	0.74	0.91	0.86	0.69	0.88	1.0	0.88	0.1	-0.88	0.91	-0.02	1.0	0.76	0.76	0.83	0.91	0.92	-0.86	0.91		0.68	0.88	-0.84	0.86
Other Current Assets	0.72	0.68	0.69	0.75	0.7	0.6	0.82	0.65	0.38	0.13	-0.85	0.84	-0.08	0.66	0.53	0.58	0.71	0.7	0.75	-0.76	0.84	0.68		0.73	-0.69	0.7
Other Stockholder Equity	0.94	0.88	0.71	0.87	0.95	0.82	0.96	0.87	0.74	-0.08	-0.91	0.89	0.15	0.88	0.79	0.83	0.92	0.98	0.98	-0.94	0.96	0.88	0.73		-0.94	0.95
Total Liab	-0.94	-0.84	-0.61	-0.75	-0.98	-0.75	-0.97	-0.81	-0.66	0.09	0.82	-0.79	-0.16	-0.82	-0.62	-0.63	-0.91	-0.97	-0.9	0.99	-0.93	-0.84	-0.69	-0.94		-0.98
Net Invested Capital	0.99	0.86	0.72	0.83	1.0	0.82	0.97	0.84	0.68	-0.22	-0.82	0.82	0.29	0.85	0.71	0.71	0.97	0.98	0.92	-0.98	0.94	0.86	0.7	0.95	-0.98

Click cells to compare fundamentals

Relay Therapeutics Account Relationship Matchups

Relay Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	799.8M	1.0B	1.1B	844.0M	871.3M	855.6M
Short Long Term Debt Total	24.4M	22.9M	57.7M	53.5M	48.5M	36.5M
Other Current Liab	4.2M	12.1M	44.6M	1.2M	23.2M	13.5M
Total Current Liabilities	13.6M	24.3M	63.7M	30.3M	50.7M	31.7M
Total Stockholder Equity	763.3M	897.8M	950.2M	752.0M	777.8M	605.0M
Other Liab	156K	3K	65.3M	32.4M	37.2M	21.6M
Net Tangible Assets	(180.4M)	763.3M	895.5M	947.9M	1.1B	1.1B
Property Plant And Equipment Net	28.8M	27.3M	75.4M	68.9M	57.7M	46.1M
Current Deferred Revenue	3.4M	5.6M	248K	14.9M	7.7M	6.2M
Net Debt	(423.2M)	(935.2M)	(941.2M)	(90.3M)	(75.8M)	(79.6M)
Retained Earnings	(404.2M)	(768.1M)	(1.1B)	(1.4B)	(1.7B)	(1.7B)
Accounts Payable	6.4M	8.3M	10.6M	9.2M	14.1M	9.5M
Cash	447.6M	958.1M	998.9M	143.7M	124.3M	118.1M
Non Current Assets Total	29.7M	32.2M	80.3M	73.9M	62.1M	49.5M
Cash And Short Term Investments	678.1M	958.1M	998.9M	750.1M	781.3M	776.9M
Common Stock Total Equity	4K	90K	109K	121K	139.2K	71.9K
Common Stock Shares Outstanding	42.6M	95.1M	112.2M	122.6M	142.9M	82.1M
Short Term Investments	230.4M	678.0M	847.1M	606.4M	657.0M	523.7M
Liabilities And Stockholders Equity	799.8M	1.0B	1.1B	844.0M	871.3M	855.6M
Non Current Liabilities Total	22.9M	86.3M	85.8M	61.7M	42.8M	40.6M
Capital Surpluse	8.7M	1.2B	1.7B	2.0B	2.3B	2.4B
Capital Lease Obligations	24.4M	22.9M	57.7M	53.5M	48.5M	36.5M
Other Current Assets	9.4M	13.2M	15.4M	3.3M	27.9M	29.3M
Other Stockholder Equity	1.2B	1.7B	2.0B	2.2B	2.5B	1.4B
Total Liab	36.5M	110.6M	149.6M	92.0M	93.5M	182.3M
Net Invested Capital	763.3M	897.8M	950.2M	752.0M	777.8M	605.0M
Property Plant And Equipment Gross	28.8M	41.7M	93.8M	92.5M	86.6M	59.5M
Total Current Assets	770.1M	976.2M	1.0B	770.1M	809.2M	806.1M
Accumulated Other Comprehensive Income	64K	(1.1M)	(10.4M)	(196K)	(991K)	(1.0M)
Capital Stock	90K	109K	121K	127K	168K	97.7K
Non Current Liabilities Other	22.9M	86.3M	32.4M	13.2M	15.2M	28.5M
Net Working Capital	756.5M	951.9M	955.8M	739.8M	758.5M	774.4M
Short Term Debt	3.0M	3.7M	8.6M	5.0M	5.7M	4.3M
Common Stock	90K	109K	121K	127K	168K	97.7K
Property Plant Equipment	31.7M	28.8M	6.5M	11.6M	10.5M	13.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Relay Stock Analysis

When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Relay Historical Balance Sheet

Relay Therapeutics Inventory

14.62 Million

About Relay Balance Sheet Analysis

Relay Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Relay Therapeutics balance sheet Correlations

Relay Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Relay Therapeutics balance sheet Accounts

Also Currently Popular

Additional Tools for Relay Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Property Plant And Equipment Net	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 1.0	Short Long Term Debt Total
Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Net Invested Capital	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net

Cash	- 1.0	Net Debt
Non Current Liabilities Total	- 0.99	Net Tangible Assets
Net Invested Capital	- 0.98	Total Liab
Net Invested Capital	- 0.98	Non Current Liabilities Total
Total Liab	- 0.98	Total Stockholder Equity
Non Current Liabilities Total	- 0.98	Total Stockholder Equity